Efeitos da dexametasona em dose única em pacientes com síndrome da resposta inflamatória sistêmica
Palavras-chave:
Síndrome séptica, Sepse, Inflamação, Corticosteróides, DexametasonaResumo
CONTEXTO E OBJETIVO: A síndrome da resposta inflamatória sistêmica (SRIS) acomete muitos pacientes internados em unidades de terapia intensiva. A evolução destes pacientes com SRIS para sepse, choque séptico e síndrome da disfunção de múltiplos órgãos (SDMO) pode conduzi-los rapidamente para o óbito. A proposta do trabalho é avaliar a eficácia da dexametasona em dose única como tratamento da SRIS. TIPO DE ESTUDO E LOCAL: Estudo prospectivo, aleatório, duplamente encoberto, realizado na Unidade de Terapia Intensiva pós-operatória (Unidade de Apoio Cirúrgico) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. MÉTODOS: Foram estudados 29 pacientes com diagnóstico de SRIS. Os participantes foram aleatoriamente divididos em dois grupos que receberam dexametasona (0,2 mg/kg em dose única) ou placebo após o diagnóstico de SRIS. Os pacientes foram acompanhados durante sete dias de internação na UTI através do escore SOFA (Sequential Organ Failure Assessment). RESULTADOS: Os pacientes que receberam dexametasona apresentaram melhora do sistema respiratório no primeiro dia, com aumento da relação PaO2/FiO2 (p < 0,05). Entre os pacientes que faziam uso de vasopressores, os que receberam dexametasona tiveram diminuição da necessidade destas medicações nos primeiros dois dias após a dose de dexametasona (p < 0,05). CONCLUSÃO: A dexametasona diminuiu a necessidade de medicações vasopressoras e causou aumento da relação PaO2/FiO2 no primeiro dia após sua administração. Apesar destes efeitos, a dexametasona em dose única não bloqueou a evolução dos pacientes com SRIS.
Downloads
Referências
Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644-55.
Bone RC. Sepsis, sepsis syndrome, and systemic inflamma- tory response syndrome (SIRS). Gulliver in Laputa. JAMA. 1995;273(2):155-6.
Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflamma- tory response syndrome (SIRS). A prospective study. JAMA. 1995;273(2):117-23.
Christman JW, Lancaster LH, Blackwell TS. Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med. 1998;24(11):1131-8.
Janssen-Heininger YM, Poynter ME, Baeuerle PA. Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappa B. Free Radic Biol Med. 2000;28(9):1317-27.
Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of I kappa B alpha in me- diation of immunosuppression by glucocorticoids. Science. 1995;270(5234):283-6.
Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270(5234):286-90.
Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med. 1996;24(1):163-72.
Bihari DJ, Tinker J. Steroids in intensive care. Br J Hosp Med. 1982;28(4):323-4, 328-30.
Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med. 1998;26(4):645-50.
Schumer W. Controversy in shock research. Pro: The role of steroids in septic shock. Circ Shock. 1981;8(6):667-71.
Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med. 1995;23(8):1430-9.
Demling RH, Smith M, Gunther R, Wandzilak T. Endotoxin- induced lung injury in unanesthetized sheep: effect of methyl- prednisolone. Circ Shock. 1981;8(3):351-60.
Hughes GS Jr. Naloxone and methylprednisolone sodium suc- cinate enhance sympathomedullary discharge in patients with septic shock. Life Sci. 1984;35(23):2319-26.
Kass EH. High-dose corticosteroids for septic shock. N Engl J Med. 1984;311(18):1178-9.
Sheagren JN. Septic shock and corticosteroids. N Engl J Med. 1981;305(8):456-8.
Lederer V. Betamethasone sodium phosphate injection: high- dose regimen in septic shock. Clin Ther. 1984;6(5):719-26.
Lefering R, Neugebauer E. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med. 1995;23(7):1294- 303.
Nicholson DP. Corticosteroids in the treatment of septic shock and the adult respiratory distress syndrome. Med Clin North Am. 1983;67(3):717-24.
Ottosson J, Brandberg A, Erikson B, Hedman L, Dawidson I, Söderberg R. Experimental septic shock - effects of corticoste- roids. Circ Shock. 1982;9(6):571-7.
Saito T, Takanashi M, Gallagher E, et al. Corticosteroid effect on early beta-adrenergic down-regulation during circulatory shock: hemodynamic study and beta-adrenergic receptor assay. Intensive Care Med. 1995;21(3):204-10.
Briegel J, Kellermann W, Forst H, et al. Low-dose hydrocor- tisone infusion attenuates the systemic inflammatory response syndrome. The Phospholipase A2 Study Group. Clin Investig. 1994;72(10):782-7.
Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortal- ity in patients with septic shock. JAMA. 2002;288(7):862-71.
Carlet J. From mega to more reasonable doses of corticosteroids: a decade to recreate hope. Crit Care Med. 1999;27(4):672-4.
Abraham E, Evans T. Corticosteroids and septic shock. JAMA. 2002;288(7):886-7.
Briegel J, Forst H, Haller M, et al. Stress doses of hydro- cortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med. 1999;27(4):723-32.
Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respira- tory distress syndrome: a randomized controlled trial. JAMA. 1998;280(2):159-65.
Reade MC, Young JD. Consent for observational studies in critical care: time to open Pandora’s Box. Anaesthesia. 2003;58(1):1-3.
Sibbald WJ, Doig G, Inman KJ. Sepsis, SIRS and infection. Intensive Care Med. 1995;21(4):299-301.
Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JG, Gilman AG, Limbird LE, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 9th ed. St Louis: McGraw-Hill; 1996. p. 1459-85.
Cook R, Cook D, Tilley J, Lee K, Marshall J, Canadian Critical Care Trials Group. Multiple organ dysfunction: baseline and se- rial component scores. Crit Care Med. 2001;29(11):2046-50.
Muckart DJ, Bhagwanjee S. American College of Chest Physi- cians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med. 1997;25(11):1789-95.
Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunc- tion/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707-10.
Vincent JL, de Mendonça A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society on Intensive Care Medicine. Crit Care Med. 1998;26(11):1793-800.
Bernard GR. Quantification of organ dysfunction: seeking standardization. Crit Care Med. 1998;26(11):1767-8.
Timsit JF, Fosse JP, Troché G, et al. Calibration and discrimina- tion by daily Logistic Organ Dysfunction scoring comparatively with daily Sequential Organ Failure Assessment scoring for predicting hospital mortality in critically ill patients. Crit Care Med. 2002;30(9):2003-13.
Pettila V, Pettila M, Sarna S, Voutilainen P, Takkunen O. Comparison of multiple organ dysfunction scores in the predic- tion of hospital mortality in the critically ill. Crit Care Med. 2002;30(8):1705-11.
Póvoa P, Almeida E, Moreira P, et al. C-reactive protein as an indicator of sepsis. Intensive Care Med. 1998;24(10):1052-6.
Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003;29(4):530-8.
MacLaren R, Jung R. Stress-dose corticosteroid therapy for sepsis and acute lung injury or acute respiratory distress syndrome in critically ill adults. Pharmacotherapy. 2002;22(9):1140-56.
Manglik S, Flores E, Lubarsky L, Fernandez F, Chhibber VL, Tayek JA. Glucocorticoid insufficiency in patients who present to the hospital with severe sepsis: a prospective clinical trial. Crit Care Med. 2003;31(6):1668-75.
Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348(2):138-50.
Matot I, Sprung CL. Corticosteroids in septic shock: resurrection of the last rites? Crit Care Med. 1998;26(4):627-30.
Carlet J, International Sepsis Forum. Immunological therapy in sepsis: currently available. Intensive Care Med. 2001;27(Suppl 1):S93-103.
Meduri GU, Kanangat S. Glucocorticoid treatment of sepsis and acute respiratory distress syndrome: time for a critical reappraisal. Crit Care Med. 1998;26(4):630-3.
Thompson BT. Glucocorticoids and acute lung injury. Crit Care Med. 2003;31(4 Suppl):S253-7.
Martin GS, Bernard GR, International Sepsis Forum. Airway and lung in sepsis. Intensive Care Med. 2001;27(Suppl 1): S63-79.
Kobayashi S, Gando S, Morimoto Y, Nanzaki S, Kemmotsu
O. Serial measurement of arterial lactate concentrations as a prognostic indicator in relation to the incidence of disseminated intravascular coagulation in patients with systemic inflammatory response syndrome. Surg Today. 2001;31(10):853-9.
Dinarello CA. The Acute-Phase response. In: Bennett JC, Plum F, editors. Cecil Textbook of Medicine. 20th ed. Philadelphia: Saunders; 1996.p. 1567-9.
Reny JL, Vuagnat A, Ract C, Benoit MO, Safar M, Fagon JY. Diagnosis and follow-up of infections in intensive care patients: value of C-reactive protein compared with other clinical and biological variables. Crit Care Med. 2002;30(3):529-35.
Tschaikowsky K, Hedwig-Geissing M, Schiele A, Bremer F, Schywalsky M, Schüttler J. Coincidence of pro- and anti-inflam- matory responses in the early phase of severe sepsis: Longitudinal study of mononuclear histocompatibility leukocyte antigen-DR expression, procalcitonin, C-reactive protein, and changes in T-cell subsets in septic and postoperative patients. Crit Care Med. 2002;30(5):1015-23.
Soares AJ, David CMN. A avaliação do comportamento da proteína C-reativa em pacientes com sepse na UTI. Rev Bras Ter Intensiva. 2002;14(4):156-65.
Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlini A. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med. 2003;31(6):1737-41.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
